EGFR and non-small cell lung carcinoma: For EGFR exon 20 insertion mutations, amivantamab301 and sunvozertinib,401 have been approved by the FDA and NMPA, respectively, for second-line treatment of locally advanced or metastatic NSCLC, based on the data from the CHRISTYS trial and a series of WU-KONG trials.